Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-reduced versus standard conditioning before allogeneic stem cell transplantation in MDS or secondary AML
2005-002011-24Phase 3Completed
- Sponsor
- EBMT
- Start
- Apr 2008
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of busulfan, cyclophosphamide in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by EBMT. Started Apr 2008; status: completed.
02
Drugs
busulfancyclophosphamide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-002011-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002011-24.